Current Report Filing (8-k)
August 10 2018 - 3:47PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form
8-K
Current
Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 10, 2018
ENDOLOGIX, INC.
(Exact
name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-28440
|
|
68-0328265
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
2 Musick, Irvine, CA 92618
(Address of principal executive offices, with zip code)
(949) 595-7200
(Registrants telephone number, including area code)
N/A
(Former name or
former address, if changed since last report)
Check the
appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this
chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§ 240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 8.01 Other Events.
Endologix, Inc. (the Company) has updated its currently estimated timeline for anticipated U.S. Food and Drug Administration (FDA)
approval of the Companys premarket approval (PMA) application for its Nellix 3.5 endovascular aneurysm sealing system. Based on current enrollment rates in the Companys EVAS2 clinical confirmatory study and other factors, the
Company estimates that FDAs approval determination will occur in the first half of 2021.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
ENDOLOGIX, INC.
|
|
|
|
|
Date: August 10, 2018
|
|
|
|
By:
|
|
/s/ Vaseem Mahboob
|
|
|
|
|
|
|
Vaseem Mahboob
|
|
|
|
|
|
|
Chief Financial Officer
|
3
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Apr 2023 to Apr 2024
Real-Time news about Endologix Inc (NASDAQ): 0 recent articles
More Endologix Inc /de/ News Articles